Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Crizotinib--latest champion in the cancer wars?

Hallberg B, Palmer RH.

N Engl J Med. 2010 Oct 28;363(18):1760-2. doi: 10.1056/NEJMe1010404. No abstract available.

PMID:
20979477
2.

More on crizotinib.

Shen L, Ji HF.

N Engl J Med. 2011 Feb 24;364(8):777-8. doi: 10.1056/NEJMc1013325. No abstract available.

PMID:
21345111
3.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, Tanio Y, Mano H; ALK Lung Cancer Study Group.

N Engl J Med. 2010 Oct 28;363(18):1734-9. doi: 10.1056/NEJMoa1007478.

4.

Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.

Saraceni C, Li PM, Gainor JF, Stopyra GA, Friedman EL.

J Thorac Oncol. 2015 Jul;10(7):1116-7. doi: 10.1097/JTO.0000000000000409. No abstract available.

5.

Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.

Perez CA, Velez M, Raez LE, Santos ES.

Lung Cancer. 2014 May;84(2):110-5. doi: 10.1016/j.lungcan.2014.02.001. Epub 2014 Feb 8. Review.

PMID:
24598368
6.

Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.

Okamoto I, Nakagawa K.

Cancer Sci. 2012 Aug;103(8):1391-6. doi: 10.1111/j.1349-7006.2012.02327.x. Epub 2012 Jun 17. Review.

7.

Cancer: broken genes in solid tumours.

Meyerson M.

Nature. 2007 Aug 2;448(7153):545-6. No abstract available.

PMID:
17671492
8.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H.

Nature. 2007 Aug 2;448(7153):561-6. Epub 2007 Jul 11.

PMID:
17625570
9.

[Personalized medicine in non-small-cell carcinoma].

Iwama E, Takayama K, Baba E, Nakanishi Y.

Fukuoka Igaku Zasshi. 2014 Mar;105(3):57-66. Review. Japanese. No abstract available.

PMID:
25000657
10.

Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lung cancer: a promising feature?

Sterlacci W, Cappuzzo F, Savic S, Bubendorf L, Tzankov A.

Hum Pathol. 2010 Apr;41(4):614-5; author reply 615-616. doi: 10.1016/j.humpath.2009.11.009. Epub 2010 Feb 16. No abstract available.

PMID:
20163822
11.

Clinical response to crizotinib retreatment after acquisition of drug resistance.

Matsuoka H, Kurata T, Okamoto I, Kaneda H, Tanaka K, Nakagawa K.

J Clin Oncol. 2013 Jul 1;31(19):e322-3. doi: 10.1200/JCO.2012.46.4305. Epub 2013 May 28. No abstract available.

PMID:
23715571
12.

[The EML4-ALK fusion gene in NSCLC and the clinical progress].

Wu D, Yu H.

Zhongguo Fei Ai Za Zhi. 2011 May;14(5):435-40. doi: 10.3779/j.issn.1009-3419.2011.05.10. Review. Chinese. No abstract available.

13.

[Anaplastic lymphoma kinase with the echinoderm microtubule-associated protein-like 4, fusion gene and non-small cell lung cancer].

Xia N, Hu CP.

Zhonghua Jie He He Hu Xi Za Zhi. 2012 Feb;35(2):125-7. Review. Chinese. No abstract available.

PMID:
22455969
14.

Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.

Kim SJ, Kim DW, Kim TM, Lee SH, Heo DS, Bang YJ.

J Clin Oncol. 2012 Jun 1;30(16):e147-50. doi: 10.1200/JCO.2011.39.9766. Epub 2012 Apr 16. No abstract available.

PMID:
22508824
15.

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK.

Clin Cancer Res. 2011 Dec 1;17(23):7394-401. doi: 10.1158/1078-0432.CCR-11-1648. Epub 2011 Sep 26.

16.

Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinib.

Pennell NA.

Am J Manag Care. 2012 May;18(5 Spec No. 2):SP84-7. No abstract available.

17.

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.

Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ.

J Thorac Oncol. 2010 Dec;5(12):2044-6. doi: 10.1097/JTO.0b013e318200f9ff. No abstract available.

18.

Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer.

Solomon B.

J Clin Oncol. 2015 Mar 20;33(9):972-4. doi: 10.1200/JCO.2014.59.8334. Epub 2015 Feb 9. No abstract available.

PMID:
25667277
19.

Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.

Huang D, Kim DW, Kotsakis A, Deng S, Lira P, Ho SN, Lee NV, Vizcarra P, Cao JQ, Christensen JG, Kim TM, Sun JM, Ahn JS, Ahn MJ, Park K, Mao M.

Genomics. 2013 Sep;102(3):157-62. doi: 10.1016/j.ygeno.2013.02.006. Epub 2013 Feb 20.

20.

Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation.

van Geffen WH, Hiltermann TJ, Groen HJ.

J Thorac Oncol. 2013 Jan;8(1):e1-2. doi: 10.1097/JTO.0b013e3182762812. No abstract available.

Supplemental Content

Support Center